par Lambertini, Matteo ;Martel, Samuel;Campbell, Christine;Guillaume, Sébastien;Hilbers, Florentine FS;Schuehly, Uwe;Korde, Larissa;Abdel Azim, Hatem Hamdy ;Di Cosimo, Serena;Tenglin, Richard RC;Huober, Jens;Baselga, José;Moreno-Aspitia, Alvaro;Piccart-Gebhart, Martine ;Gelber, Richard D;de Azambuja, Evandro ;Ignatiadis, Michail
Référence Cancer
Publication Publié, 2018-10-01
Référence Cancer
Publication Publié, 2018-10-01
Article révisé par les pairs
Résumé : | Limited data exist on the safety of using anti-human epidermal growth factor receptor 2 (HER2) targeted agents during pregnancy. To date, only retrospective studies have assessed the prognosis of patients with a pregnancy after prior early breast cancer, with no data in HER2-positive patients. |